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Abstract: The hydrazide 5, that was obtained from 
 1-(4-fluorophenyl)piperazine (1), was converted to the cor-
responding carbothioamides 6a–c by the reaction with 
alkyl(aryl) isothiocyanates. The synthesis of conazole 
analogs 10a–f was performed via the intermediary of 
triazoles 7a–c. The condensation of triazoles 7a–c with 
 several  heterocyclic amines in the presence of formalde-
hyde afforded the corresponding N-aminoalkylated tria-
zoles 11–14. The effect of different catalysts and solvents 
on conventional and microwave (MW)-prompted reac-
tions was examined. The synthesized compounds were 
screened for their antimicrobial activities.
Keywords: antimicrobial activity; conazole; Mannich 
base; microwave; piperazine.
Introduction
During the past few years, the excessive use of common 
antimicrobial drugs has caused the emergence of resistant 
bacteria leading to diminished efficiency of these drugs 
[1–5]. This rapid emergence of drug resistance has now 
become a serious public health problem [6, 7]. The increas-
ing resistance problem has prompted the synthesis of new 
chemical entities in an effort to come up with new drugs 
with better therapeutic properties including better toler-
ability, less side effects and low tendency to resistance [8].
In recent years, the concept of hybrid molecules 
which contain two or more pharmacophore groups bound 
together covalently in one molecular framework has been 
introduced. It has been suggested that such compounds 
may inhibit two or more conventional targets simultane-
ously. This multiple target strategy has already resulted 
in the development of a number of bioactive hybrid 
 molecules [9].
Multicomponent reactions with at least three com-
ponents in the one-pot process to give a single product 
represent a unique strategy leading to the formation of 
various bioactive molecules, due to their convergence, 
low energy consumption, minimum waste production, 
facile execution, high selectivity and productivity [10–12]. 
On the other hand, microwave (MW) techniques are more 
dynamic and effective than the conventional methods 
[13–16]. The success of combinatorial chemistry aiming 
at the discovery of new drug candidates depends on the 
advances in the one-pot multicomponent reactions with 
ecofriendly procedures. Solvent is one of the key factors 
when it is used in large quantities [11]. Most organic sol-
vents are toxic, and they should be used in minimum 
quantities as far as possible or should be replaced with 
nontoxic alternatives, preferably with water [17–23].
A piperazine ring is a core structure of many mar-
keted drugs including fluoroquinolone antibiotics such as 
norfloxacin, ciprofloxacin and levofloxacin [24–29]. Sub-
stituted piperazines often show increased antimicrobial 
activity probably by enhancing lipophilicity of the mol-
ecule [30]. In biologically active products, piperazine is 
often present as a fused or oxidized form [31] or is substi-
tuted with an azole (1,2,4-triazole and/or imidazole) [32].
Results and discussion
Chemistry
Synthesis of the target compounds was carried out as 
illustrated in Schemes 1 and 2. The key substrate 5 was 
prepared from 1-(4-fluorophenyl)piperazine (1) by con-
ventional and also MW-assisted methods in four steps. 
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The  treatment of 5 with phenyl, benzyl or ethyl isothio-
cyanate generated the corresponding carbothioamide 
derivatives 6a–c. The reactions were conducted in dichlo-
romethane at room temperature and under MW irradia-
tion in the attempts to maximize the yields of the products 
and minimize the reaction times. The reaction time for 
complete consumption of starting materials was lowered 
from 24 h for a conventional heating to a remarkable 8 min 
using MW irradiation. The optimal MW power in terms of 
yield and product stability was assessed at 150 W at 125°C 
in a closed vessel without any solvent. Products 6a–c 
were obtained in yields of 91%–97%.
The treatment of compounds 6a–c with a base yielded 
1,2,4-triazole derivatives 7a–c. The ring closure reactions 
leading to compounds 7a–c were identified with IR, 1H 
NMR, 13C NMR, mass spectral and elemental analyses. Our 
previous studies [5, 24, 30, 33–35] have demonstrated that 
the 3-mercapto-1,2,4-triazoles can exist in a thione or thiol 
tautomeric form and this conclusion is also true for com-
pounds 7a–c. On the basis of analysis of the spectral data 
(see Experimental section), it can be suggested that 7a,b 
and 7c exist preferentially in the respective thione and 
thiol forms.
Alkylation of compounds 7a–c with 2-bromo-1-(4-chlo-
rophenyl)ethanone in ethanol afforded the corresponding 
compounds 8a–c. Compared with a conventional heating, 
MW irradiation decreased the reaction time from 22 h to 
25 min and increased the yields from 22%–35% to 52%–
75%. The best yields were obtained at 150°C for 25 min at 
150 W maximum power. Compounds 7a–c can, in princi-
ple, be alkylated at the sulfur or nitrogen atom. The struc-
tures of the resultant products 8a–c were suggested (see 
Experimental) based on the spectral data but additional 
work is needed to support this analysis. The reduction 
of carbonyl group with NaBH4 in 8a–c to alcohol gave 












































































6a–9a, 10a–c:  R = Ph
6b–9b, 10d–f:  R = Bn
6c–9c, 10g–i:   R = Et
10a: X = Y = H; Z = Cl   10d: X = Y = H; Z = Cl
10b: X = Z = Cl; Y = H   10e: X = Z = Cl; Y = H
















Scheme 1 Synthetic route for compounds 2–10. (i): 3,4-difluoronitrobenzene, NaHCO3 ; (ii): H2NNH2, Pd-C; (iii): BrCH2COOEt, Et3N; 
(iv): H2NNH2, EtOH; (v): isothiocyanate, DCM; (vi): 2N NaOH, H2O + EtOH; (vii): 4-ClC6H4COCH2Br, Na, EtOH; (viii): NaBH4; (ix): NaH, THF, 
 substituted benzyl chloride.
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classical heating and MW irradiation. For MW-prompted 
reactions leading to the formation of compounds 9a–c, the 
reduction of compound 9a was selected as model and the 
effects of various reaction parameters, including solvent, 
temperature, time and MW power were examined. The 
results showed that the best yield was obtained in ethanol 
with MW irradiation at 100 W and 100°C for 20 min. The 
synthesis of compounds 10a–f was achieved by treatment 
of compounds 9a–c with substituted benzyl chlorides, 
namely 4-chloro-, 2,4-dichloro- and 2,6-dichlorobenzyl 
chlorides in the presence of NaH under MW-mediated 
and conventional conditions. In order to improve the MW 
conditions, the reaction leading to the formation of 10a 
was selected as a model reaction and the effects of several 
parameters including time, power and solvent were exam-
ined. After optimization of the conditions for the prepa-
ration of 10a, the synthesis of the remaining compounds 
10b–i was carried out. Again, it should be noted that the 
structural assignments for products 9a–c and 10a–i are 
tentative and additional work is needed to show the N- or 
S-alkylation site (Scheme 1).
The aminoalkylation of compounds 7a–c with several 
secondary amines, namely norfloxacin (for 11a–c), cipro-
floxacin (for 12a–c), thiomorpholine (for 13a,b) and phe-
nylpiperazine (for 14) in the presence of formaldehyde 
was conducted under the MW-assisted Mannich reaction 
conditions (Scheme 2). Initially, to optimize the conditions 
for this one-pot three-component reaction, compound 11a 
was selected as a model product, and the model reactions 
were performed in polar solvents and without solvent in 
the presence of different Lewis and Bronsted acid catalysts 
such as p-TSA, FeCl3, InCl3 and HCl. The effects of various 
reaction parameters, including temperature, catalyst, 
solvent, MW power and time were examined. In all cases, 
completion of the reaction was monitored by the thin-layer 
chromatography (TLC) analysis. The solvent-free reaction 
with HCl as a catalyst constituted the optimal method yield-
ing the desired product 11a within 20 min at 70 W with the 
yield of 83%. The spectral analysis of products 11–14 (see 
Experimental section) strongly suggested the N-alkylated 
thione structure in all cases as shown in Scheme 2.
Mannich bases have been used previously as poten-
tially useful prodrug candidates for imides, amides, 
amines, hydantoin and urea derivatives. It is believed that 
the N-alkyl group in Mannich bases increases the lipophi-
licity of the parent amines at physiological pH values by 
decreasing their protonation that results in enhancement 
of absorption through biomembranes [33].
Biological activity
All compounds were tested for their antimicrobial activi-
ties, and the results for active derivatives are presented 
in Table  1. Compounds of low activity are not included. 
No clear structure-activity relationships can be detected, 
indicating that the antibacterial activity is significantly 
affected by the nature of the compound. It is evident from 
Table 1 that the aminoalkylation of triazoles 7a–c with 


































11a, 12a: R = Ph
11b, 12b, 13a: R = Bn
11c, 12c, 13b: R = Et
11a–c: R′ = Et
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gives rise to the excellent activity of the resultant prod-
ucts 11a–c and 12a–c toward the test bacteria with the 
minimum inhibitory concentration (MIC) values between 
0.24 and 1.9 μg/mL. It can be suggested that excellent activ-
ity of these compounds is due to the presence of a fluoro-
quinolone core in their structures. In fact, the MIC values 
of compounds 11a–c are similar to the MIC values of nor-
floxacine and ciprofloxacine. Among the aminoalkylated 
triazoles, especially the ones containing an aromatic 
substituent at the position 4 of a 1,2,4-triazole ring, com-
pounds 11a,b and 12a,b are the most active. Compounds 
2–9 except 8b and 10a did not exhibit noteworthy activity 
toward the test microorganisms.
Experimental
Chemistry
The chemicals were purchased from Fluka Chemie AG (Buchs, Swit-
zerland) and used without purification. Melting points were deter-
mined in open capillaries on a Büchi B-540 melting point apparatus 
and are uncorrected. Reactions were monitored by TLC on silica 
gel 60 F254 aluminum sheets. The mobile phase was ethyl acetate/
diethyl ether (1 : 1) and detection was made using UV light. Fourier 
transform infrared (FT-IR) spectra were recorded using a Perkin 
Elmer 1600 series spectrometer. 1H NMR and 13C NMR spectra were 
registered in DMSO-d6 on a Bruker Avene II 400 NMR spectrometer 
(400 MHz for 1H and 100 MHz for 13C). The elemental analysis was 
performed on a Costech Elemental Combustion System CHNS-O 
elemental analyzer. The electron ionization (EI) mass spectra were 
obtained on a Quattro GC-MS (70 eV) instrument. MW-assisted reac-
tions were performed in a CEM Discovery reactor.
1-(2-Fluoro-4-nitrophenyl)-4-(4-fluorophenyl)-
piperazine (2)
Method 1 A mixture of 1-(4-fluorophenyl)-piperazine (10  mmol), 
3,4-difluoronitrobenzene (10 mmol) and NaHCO3 (30 mmol) in ace-
tonitrile (50  mL) was heated under reflux for 8  h. Concentration 
under reduced pressure resulted in the formation of a yellow solid 
that was treated with water, filtered off and crystallized from ethyl 
acetate to give the target yellow compound in a 64% yield.
Method 2 A mixture of 1-(4-fluorophenyl)-piperazine (1  mmol), 
NaHCO3 (3 mmol) and 3,4-difluoronitrobenzene (1 mmol) was irra-
diated in a MW reactor with pressure control at 125°C, 150  W for 
30 min. The yellow solid obtained was treated with water, filtered 
off and crystallized from ethyl acetate to give the target yellow com-
pound in a 90% yield; mp 95–96°C; IR: νmax 3081 (aromatic CH), 
2975 (aliphatic CH), 1503 and 1337 cm − 1 (NO2); 1H NMR: δ 3.23 (brs, 
4H, 2CH2), 3.42 (brs, 4H, 2CH2), 6.99–7.02 (m, 2H, ArH), 7.05–7.10 (m, 
2H, ArH), 7.21 (t, 1H, ArH, J = 8.8 Hz), 8.02 (d, 2H, ArH, J = 11.2 Hz);13C 
NMR: δ 49.4 (2CH2), 49.5 (CH2), 49.5 (CH2), Aryl-C: [112.6 and 112.8 
(d, CH, J = 20 Hz), 115.7 and 115.9 (d, 2CH, J = 20 Hz), 117.9 and 118.0 
(d, 2CH, J = 10  Hz), 118.5 and 118.6 (d, CH, J = 10  Hz), 121.7 (CH), 
139.9 and 140.0 (d, C, J = 10  Hz), 145.5 and 145.6 (d, C, J = 10  Hz), 
148.0 (C), 151.3 and 153.8 (d, C, JC − F = 250  Hz), 155.6 and 157.9 (d, 
C, JC−F = 230 Hz)]; MS: m/z 360.57 ([M + 2 + K] +, 93), 321.45 ([M + 2] +, 
33), 193.14 (42), 150.94 (49), 135.03 (100), 117.04 (55%). Anal. Calcd 
for C16H15F2N3O2: C, 60.18; H, 4.73; N, 13.16. Found: C, 60.58; H, 4.65; 
N, 13.01.
3-Fluoro-4-[4-(4-fluorophenyl)piperazin-1-yl]aniline (3)
Method 1 Pd/C catalyst (5 mmol) and hydrazine hydrate (50 mmol) 
were added to the solution of compound 2 (10  mmol) in 1-butanol 
(50 mL) and the mixture was heated under reflux for 15 h and then 
the catalyst was removed by filtrating the hot mixture on celite. Con-
centration under reduced pressure resulted in the formation of an 
oily mass that was crystallized from ethanol to give the target white 
compound in a 53% yield.
Method 2 Pd/C (5 mmol) catalyst and hydrazine hydrate (5 mmol) 
were added to the solution of compound 2 (10  mmol) in 1-butanol 
and the mixture was irradiated in a MW reactor with pressure con-
trol at 150°C, 200 W for 50 min. Then, the catalyst was separated by 
filtration and the solvent was evaporated under reduced pressure. 
The white solid obtained was crystallized from ethanol to give the 
target compound in a 71% yield; mp 156–157°C; IR: νmax 3500 and 
3407 (NH2), 3060 (aromatic CH), 2972 cm − 1 (aliphatic CH); 1H NMR: 
δ 2.96 (brs, 4H, 2CH2), 3.17 (brs, 4H, 2CH2), 5.02 (s, 2H, NH2), 6.32–6.78 
(m, 2H, ArH), 6.80 (t, 1H, ArH, J = 9.2  Hz), 6.95–6.98 (m, 2H, ArH), 
7.03–7.07 (m, 2H, ArH); 13C NMR: δ 49.8 (2CH2), 51.7 (2CH2), Aryl-C: 
[102.3 and 102.5 (d, CH, J = 20  Hz), 110.05 (CH), 115.6 and 115.8 (d, 
2CH, J = 20 Hz), 117.7 and 117.8 (d, 2CH, J = 10 Hz), 121.1 (CH), 129.4 and 
129.5 (d, C, J = 10 Hz), 145.9 and 146.0 (d, C, J= 10 Hz), 148.4 (C), 155.4 
and 157.7 (d, C, JC−F = 230 Hz), 155.6 and 158.0 (d, C, JC−F = 240 Hz)]; MS: 
Table 1 Screening for antimicrobial activity.
Comp. 
No
Ec Yp Pa Sa Ef Bc Ms
8b – – 500 125 125 125 3.91
10a – – – 15.6 15.6 – 500
11a < 0.24 0.49 1.95 0.49 0.98 < 0.24 < 0.24
11b 0.24 0.49 1.95 < 0.24 0.98 < 0.24 < 0.24
11c – 1.9 1.9 1.9 – 1.9 3.9
12a < 0.24 0.49 1.95 0.49 0.98 < 0.24 < 0.24
12b < 0.24 0.49 < 0.24 < 0.24 0.98 < 0.24 < 0.24
12c – < 1 < 1 < 1 – < 1 < 1
Amp. 10 18 > 128 10 35 15 –
Norf. < 0.24 < 0.24 < 0.24 < 0.24 < 0.24 < 0.24 < 0.24
Cip. < 0.24 < 0.24 < 0.24 < 0.24 < 0.24 < 0.24 < 0.24
Strep. 4
Ec, Escherichia coli ATCC 25922; Yp, Yersinia pseudotuberculosis 
ATCC 911; Pa, Pseudomonas aeruginosa ATCC 43288; Sa, Staphy-
lococcus aureus ATCC 25923; Ef, Enterococcus faecalis ATCC 29212; 
Bc, Bacillus cereus 702 Roma; Ms, M. smegmatis ATCC607; Amp., 
Ampicillin; Strep., streptomycin; Norf., Norloxacin; Cip., Ciprofloxa-
cin; –, no activity.
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m/z 290.38 ([M + 1] +, 21), 181.26 (100), 138.18 (79%). Anal. Calcd for 
C16H17F2N3: C, 66.42; H, 5.92; N, 14.52. Found: C, 66.58; H, 5.85; N, 14.31.
Ethyl 2-{3-fluoro-4-[4-(4-fluorophenyl)piperazin-1-yl]
phenyl}amino)acetate (4)
Method 1 A mixture of compound 3 (10  mmol) and triethylamine 
(15  mmol) in dry tetrahydrofuran (50  mL) was treated dropwise at 
0–5°C with ethyl bromoacetate (10  mmol). Then, the mixture was 
allowed to reach room temperature and was stirred for an additional 
24 h. The precipitated triethylammonium salt was removed by filtra-
tion. Concentration under reduced pressure resulted in the formation 
of a brown solid that was crystallized from ethanol/water (1 : 3) to 
give the target compound in a 47% yield.
Method 2 Triethylamine (1.5  mmol) was added dropwise at  0–5°C 
to the mixture of compound 3 (1  mmol) and ethyl bromoacetate 
(1 mmol). Then, the mixture was irradiated in a MW reactor with pres-
sure control at 70°C, 70 W for 8 min. Water was added and the result-
ant solid was filtered off and crystallized from ethanol/water (1 : 3) to 
give the target brown compound in a 88% yield; mp 131–132°C; IR: 
νmax 3384 (NH), 3084 (aromatic CH), 1721 cm − 1 (C=O); 1H NMR: δ 1.19 
(t, 3H, CH3, J = 7.2 Hz), 2.95 (brs, 4H, 2CH2), 3.17 (brs, 4H, 2CH2), 3.86 
(d, 2H, CH2, J = 8.0 Hz), 4.11 (q, 2H, CH2, J = 6.8 Hz), 5.03 (brs, 1H, NH), 
6.31–6.39 (m, 2H, ArH), 6.81 (t, 1H, ArH, J = 8.0 Hz), 6.96–6.99 (m, 2H, 
ArH), 7.03–7.08 (m, 2H, ArH); 13C NMR: δ 14.6 (CH3), 45.4 (CH2), 46.3 
(CH2), 49.9 (CH2), 51.6 (CH2), 54.4 (CH2), 60.7 (CH2), Aryl-C: [100.9 and 
101.2 (d, CH, J = 20 Hz), 102.3 and 102.5 (d, CH, J = 20 Hz), 115.6 and 
115.8 (d, 2CH, J = 20  Hz), 117.6 and 117.7 (d, CH, J = 10  Hz), 117.7 and 
117.8 (d, 2CH, J = 10  Hz), 129.5 and 129.9 (d, C, J = 40  Hz), 145.5 and 
145.6 (d, C, J = 10 Hz), 145.9 and 146.0 (d, C, J = 10 Hz), 148.4 and 155.4 
(d, C, JC−F = 700 Hz), 155.6 and 158.0 (d, C, JC−F = 240 Hz)], 171.6 (C=O); 
MS: m/z 376.36 ([M] +, 12), 188.22 (99), 160.19 (100%). Anal. Calcd for 
C20H23F2N3O2: C, 63.99; H, 6.18; N, 11.19. Found: C, 63.78; H, 6.15; N, 11.01.
2-{3-Fluoro-4-[4-(4-fluorophenyl)piperazin-1-yl]-
phenylamino}acetohydrazide (5)
Method 1 Hydrazine hydrate (25 mmol) was added to a solution of 
compound 4 (10 mmol) in ethanol and the mixture was heated under 
reflux for 10 h. Concentration under reduced pressure resulted in the 
formation of a white solid that was crystallized from ethyl acetate to 
give the target compound in a 72% yield.
Method 2 A mixture of hydrazine hydrate (2.5  mmol) and com-
pound 4 (1 mmol) was irradiated in a MW reactor with pressure con-
trol at 150°C, 125  W for 30  min. The product was crystallized from 
ethyl acetate to give white compound in a 95% yield; mp 146–148°C; 
IR: νmax 3500 and 3406 (NH2), 3304 (2NH), 1631 cm − 1 (C=O); 1H NMR: δ 
2.97 (brs, 4H, 2CH2), 3.17 (brs, 4H, 2CH2), 3.59 (d, 2H, CH2, J = 8.0 Hz), 
5.02 (brs, 2H, NH2), 5.89 (s, 1H, NH), 6.33–6.42 (m, 2H, ArH), 6.80 (t, 
1H, ArH, J = 8.8 Hz), 6.83–7.08 (m, 4H, ArH), 9.11 (s, 1H, NH); 13C NMR: 
δ 45.4 (CH2), 46.5 (CH2), 49.8 (2CH2), 51.6 (CH2), Aryl-C: [100.9 and 101.2 
(d, CH, J = 20 Hz), 102.3 and 102.5 (d, CH, J = 20 Hz), 115.6 and 115.8 
(d, 2CH, J = 20  Hz), 117.6 and 117.7 (d, CH, J = 10  Hz), 117.7 and 117.8 
(d, 2CH, J = 10  Hz), 129.5 and 129.9 (d, C, J = 40  Hz), 145.6 and 145.7 
(d, C, J = 10 Hz), 145.9 and 146.0 (d, C, J = 10 Hz), 153.5 and 155.4 (d, 
C, JC−F = 190 Hz), 155.6 and 158.0 (d, C, JC−F = 240 Hz)], 159.6 (C=O); MS: 
m/z 362.35 ([M + 1] +, 100), 290.33 (42), 174.27 (40), 155.19 (47%). Anal. 
Calcd for C18H21F2N5O: C, 59.82; H, 5.86; N, 19.38. Found: C, 60.00; H, 
5.65; N, 19.01.
General method for synthesis of compounds 6a–c
Method 1 Alkyl(aryl) isothiocyanate (10 mmol) was added to a solu-
tion of compound 5 (10 mmol) in dichloromethane and the mixture 
was stirred at room temperature for 24 h. The resultant solid was col-
lected by filtration and crystallized from acetone/diethyl ether (1 : 2).
Method 2 A mixture of compound 5 (1 mmol) and alkyl(aryl) iso-
thiocyanate (1 mmol) was irradiated in a MW reactor with pressure 
control at 125°C, 150 W for 8 min without any solvent. The resultant 
solid product was crystallized from acetone/diethyl ether (1 : 2).
2-{2-[3-Fluoro-4-(4-[4-fluorophenyl]piperazin-1-yl)phenyl]
amino)acetyl}-N-phenylhydrazinecarbothioamide (6a) Yield 
75%, method 1); 97%, method 2; mp 130–133°C; IR: νmax 3341 (NH), 
3295 (NH), 3229 (2NH), 3042 (aromatic CH), 1673 (C=O), 1243  cm − 1 
(C=S); 1H NMR: δ 2.98 (brs, 2H, CH2), 3.14 (brs, 2H, CH2), 3.19 (s, 2H, 
CH2), 3.35 (s, 2H, CH2), 3.79 (s, 2H, CH2), 6.99–7.16 (m, 7H, ArH), 7.15 (t, 
1H, ArH, J = 8.0 Hz), 7.32–7.35 (m, 2H, ArH), 7.42–7.48 (m, 2H, ArH), 9.67 
(s, 1H, NH), 9.78 (s, 2H, 2NH), 10.10 (s, 1H, NH); 13C NMR: δ 45.8 (CH2), 
49.7 (CH2), 49.9 (CH2), 50.7 (CH2), 51.6 (CH2), Aryl-C: [112.4 and 112.6 
(d, CH, J = 20 Hz), 115.6 and 115.7 (d, CH, J = 10 Hz), 115.8 and 115.9 (d, 
2CH, J = 10 Hz), 117.36 and 117.7 (d, 2CH, J = 40 Hz), 119.3 and 119.4 (d, 
CH, J = 10 Hz), 128.6 (2CH), 128.8 (2CH), 128.9 (CH), 139.8 and 139.9 (d, 
C, J = 10 Hz), 141.7 (2C), 145.8 (C), 148.3 and 153.9 (d, C, JC−F = 560 Hz), 
148.4 and 155.8 (d, C, JC−F = 740 Hz)], 157.83 (C=O), 180.01 (C=S); MS: 
m/z 497.32 ([M + 1] +, 12), 425.30 (18), 309.20 (48), 174.15 (100%). Anal. 
Calcd for C25H26F2N6OS: C, 60.47; H, 5.28; N, 16.92. Found: C, 60.16; H, 
5.00; N, 16.61.
N-Benzyl-2-{2-[3-fluoro-4-(4-[4-fluorophenyl]piperazin-1-yl)phe-
nyl]amino)acetyl}hydrazinecarbothioamide (6b) Yield 70%, 
method 1, 96%, method 2; mp 160–161°C; IR: νmax 3399 (NH), 3251 
(2NH), 3146 (NH), 1667 (C=O), 1220 cm − 1 (C=S); 1H NMR: δ 2.99 (brs, 2H, 
CH2), 3.13 (brs, 2H, CH2), 3.20 (s, 2H, CH2), 3.34 (s, 2H, CH2), 3.74 (s, 2H, 
CH2), 4.74 (s, 2H, CH2), 7.04 (d, 2H, ArH, J = 16.0 Hz), 7.67 (d, 3H, ArH, 
J = 4.0 Hz), 7.29–7.34 (m, 7H, ArH), 8.16 (s, 1H, NH), 8.42 (s, 1H, NH), 
9.42 (s, 1H, NH), 9.59 (s, 1H, NH); 13C NMR: δ 48.2 (CH2), 49.7 (CH2), 49.9 
(CH2), 50.7 (CH2), 50.8 (CH2), 51.6 (CH2), Aryl-C: [115.6 and 115.7 (d, 2CH, 
J = 10 Hz), 115.8 and 115.9 (d, CH, J = 10 Hz), 117.6 (CH), 117.7 and 117.8 
(d, 2CH, J = 10 Hz), 117.8 and 117.9 (d, CH, J = 10 Hz), 127.3 (CH), 127.4 
(2CH), 128.0 (2CH), 134.4 (C), 139.4 and 139.7 (d, C, J = 30 Hz), 145.6 and 
145.7 (d, C, J = 10 Hz), 145.6 and 145.7 (d, C, J = 10 Hz), 148.3 and 153.5 
(d, C, J = 520 Hz), 148.4 and 155.4 (d, C, J = 700 Hz), 158.0 (C=O), 181.3 
(C=S); MS: m/z 511.28 ([M + 1] +, 27), 402.40 (31), 332.32 (29), 323.38 
(100), 267.19 (39), 193.29 (90%). Anal. Calcd for C26H28F2N6OS: C, 61.16; 
H, 5.53; N, 16.46. Found: C, 61.11; H, 5.19; N, 16.51.
N-Ethyl-2-{2-[3-fluoro-4-(4-[4-fluorophenyl]piperazin-1-yl)phe-
nyl]amino)acetyl}hydrazinecarbothioamide (6c) Yield 70%, 
method 1, 91%, method 2; mp 175–177°C; IR: νmax 3303 (2NH), 3272 
(NH), 3156 (NH), 3002 (aromatic CH), 2880 (aliphatic CH), 1634 
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(C=O), 1240 cm − 1 (C=S); 1H NMR: δ 1.05 (t, 3H, CH3, J = 6.8 Hz), 2.97 
(brs, 4H, 2CH2), 3.18 (brs, 4H, 2CH2), 3.36 (s, 2H, CH2), 3.59 (s, 2H, 
CH2), 4.51 (brs, 2H, 2NH), 5.89 (s, 1H, NH), 6.81–6.90 (m, 2H, ArH), 
6.98–7.06 (m, 5H, ArH), 9.12 (s, 1H, NH); 13C NMR: δ 14.8 (CH3), 45.9 
(CH2), 49.1 (CH2), 49.7 (CH2), 49.9 (CH2), 50.8 (CH2), 51.6 (CH2), Aryl-C: 
[100.9 and 101.2 (d, CH, J = 20 Hz), 102.3 and 102.5 (d, CH, J = 20 Hz), 
108.3 (CH), 115.6 and 115.8 (d, 2CH, J = 20 Hz), 117.7 and 117.8 (d, 2CH, 
J = 10 Hz), 129.9 and 130.0 (d, C, J= 10 Hz), 142.9 (C), 145.7 and 145.8 
(d, C, J = 10 Hz), 148.4 and 151.5 (d, C, JC−F= 310 Hz), 155.4 and 158.0 (d, 
C, JC−F= 260 Hz)], 157.7 (C=O), 169.7 (C=S); MS: m/z 393.27 (18), 392.27 
(96), 348.34 (100), 330.32 (40), 290.34 (67), 153.00 (76%). Anal. Calcd 
for C21H26F2N6OS: C, 56.23; H, 5.84; N, 18.74. Found: C, 56.16; H, 5.90; 
N, 18.61.
General method for synthesis of compounds 7a–c
Method 1 A solution of compound 6 (10 mmol) in water was heated 
under reflux in the presence of 2M NaOH (50 mL) for 6 h, then cooled 
to room temperature and acidified to pH 4 with 37% HCl. The result-
ant precipitate was filtered off, washed with water and crystallized 
from dimethyl sulfoxide/water (1 : 4).
Method 2 A solution of 6 (1 mmol) in 2N NaOH (5 mL) was irradiated 
in a MW reactor with pressure control at 150°C, 200  W for 15  min, 
then cooled to room temperature and acidified to pH 4 with 37% HCl. 
The resultant precipitate was filtered off, washed with water and 
crystallized from dimethyl sulfoxide/water (1 : 4).
5-[({3-Fluoro-4-[4-(4-fluorophenyl)piperazin-1-yl]phenyl}
amino)methyl]-4-phenyl-2,4-dihydro-3H-1,2,4-triazole-3-thione 
(7a) Yield 58%, method 1, 89%, method 2; mp 154–156°C; IR: νmax 
3367 (NH), 3044 (aromatic CH), 1507 (C=N), 1226 cm − 1 (C=S); 1H NMR: 
δ 2.97 (brs, 2H, CH2), 3.23 (brs, 4H, 2CH2), 3.34 (s, 4H, 2CH2), 6.99–7.08 
(m, 6H, ArH), 7.33 (t, 1H, ArH, J = 8.0 Hz), 7.42–7.48 (m, 3H, ArH), 7.54 
(t, 2H, ArH, J = 7.6 Hz), 9.55 (brs, 2H, NH); 13C NMR: δ 49.7 (2CH2), 49.8 
(CH2), 50.7 (CH2), 51.5 (CH2), Aryl-C: [101.1 and 101.3 (d, CH, J = 20 Hz), 
108.4 (CH), 115.8 and 115.9 (d, 2CH, J = 10 Hz), 117.7 and 117.8 (d, CH, 
J = 10 Hz), 117.8 and 117.9 (d, 2CH, J = 10 Hz), 128.5 (CH), 128.9 (2CH), 
129.8 (2CH), 139.8 (2C), 144.9 and 145.0 (d, C, J = 10 Hz), 148.3 and 148.4 
(d, C, J = 10 Hz), 150.7 and 155.4 (d, C, JC−F = 470 Hz), 153.4 and 157.8 
(d, C, JC−F = 440 Hz)], 168.6 (triazole C-3), 180.0 (triazole C-5); MS: m/z 
479.43 ([M + 1] +, 23), 447.52 (41), 391.45 (26), 360.61 (100), 332.39 (30), 
288.27 (30), 195.29 (60%). Anal. Calcd for C25H24F2N6S: C, 62.74; H, 
5.05; N, 17.56. Found: C, 62.67; H, 5.00; N, 17.60.
4-Benzyl-5-[({3-fluoro-4-[4-(4-fluorophenyl)piperazin-1-yl]
phenyl}amino)methyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione 
(7b) Yield 68%, method 1, 85%, method 2; mp 171–173°C; IR: νmax 
3251 (NH), 3087 (aromatic CH), 2953 (aliphatic CH), 1509 (C=N), 
1245 cm − 1 (C=S); 1H NMR: δ 2.97 (brs, 4H, 2CH2), 3.22 (brs, 4H, 2CH2), 
4.15 (d, 2H, CH2, J = 5.6 Hz), 5.33 (s, 2H, CH2), 6.37 (s, 1H, ArH), 6.83 (t, 
1H, ArH, J = 9.2  Hz), 6.96–7.07 (m, 5H, ArH), 7.28–7.34 (m, 5H, ArH), 
9.66 (brs, 2H, NH); 13C NMR: δ 46.1 (CH2), 47.2 (CH2), 49.7 (CH2), 49.8 
(CH2), 50.8 (CH2), 51.5 (CH2), Aryl-C: [101.1 and 101.3 (d, CH, J = 20 Hz), 
108.5 (CH), 115.6 and 115.7 (d, CH, J = 10 Hz), 115.8 and 115.9 (d, 2CH, 
J = 10 Hz), 117.7 and 117.8 (d, 2CH, J = 10 Hz), 127.6 (2CH), 127.8 (CH), 
128.7 (2CH), 130.3 and 130.4 (d, C, J = 10 Hz), 136.2 (C), 139.5 (C), 144.8 
and 144.9 (d, C, J = 10 Hz), 150.6 and 155.4 (d, C, JC−F = 480 Hz), 155.4 
and 157.7 (d, C, JC−F = 230 Hz)], 168.3 (triazole C-3), 181.4 (triazole C-5); 
MS: m/z 516.34 ([M + 1 + Na] +, 30), 515.34 ([M + Na] +, 91), 512.46 (100), 
493.32 ([M + 1] + 11), 461.34 (70), 447.45 (31), 360.54 (52%). Anal. Calcd 
for C26H26F2N6S: C, 63.40; H, 5.32; N, 17.06. Found: C, 63.36; H, 5.09; 
N, 16.81.
4-Ethyl-5-[({3-fluoro-4-[4-(4-fluorophenyl)piperazin-1-yl]phe-
nyl}amino)methyl]-4H-1,2,4-triazole-3-thiol (7c) Yield 52%, 
method 1, 90%, method 2; mp 177–180°C; IR: νmax 3385 (NH), 3060 
(aromatic CH), 2850 (SH), 2954 (aliphatic CH), 1506 cm − 1 (C=N); 1H 
NMR: δ 1.10 (t, 3H, CH3, J = 7.2  Hz), 3.18 (brs, 4H, 2CH2), 3.35 (brs, 
4H, 2CH2), 4.01 (q, 2H, CH2, J = 7.2  Hz), 4.34 (d, 2H, CH2, J = 5.6  Hz), 
6.99–7.09 (m, 7H, ArH), 13.63 (s, 1H, SH); 13C NMR: δ 14.63 (CH3), 
49.73 (2CH2), 49.85 (CH2), 50.75 (CH2), 51.50 (2CH2), Aryl-C: [101.0 and 
101.2 (d, CH, J = 20 Hz), 108.6 (CH), 115.6 and 115.7 (d, 2CH, J = 10 Hz), 
115.8 and 115.9 (d, 2CH, J = 10 Hz), 117.8 (CH), 134.8 and 136.4 (d, C, 
J = 160 Hz), 144.9 and 145.0 (d, C, J = 10 Hz), 148.3 (C), 150.4 and 155.5 
(d, C, JC−F = 510 Hz), 153.5 and 157.9 (d, C, JC−F = 440 Hz)], 155.9 (triazole 
C-3), 180.0 (triazole C-5); MS: m/z 432.24 ([M + 2] +, 26), 431.24 ([M + 1] +, 
100), 377.24 (26), 332.13 (24), 289.21 (36), 152.93 (24%). Anal. Calcd for 
C21H24F2N6S: C, 58.89; H, 5.62; N, 19.52. Found: C, 59.00; H, 5.70; N, 
19.61.
General method for synthesis of compounds 8a–c
Method 1 A solution of compound 7 (10 mmol) and sodium ethoxide 
prepared from metallic sodium (10  mmol) and ethanol was heated 
under reflux for 2  h. Then, 2-bromo-1-(4-chlorophenyl)ethanone 
(10 mmol) was added and the mixture was heated under reflux for an 
additional 20 h and then concentrated and the residue was treated 
with water. The resultant solid was crystallized from acetone to give 
an orange product.
Method 2 A solution of compound 7 (1 mmol) in ethanol was irradi-
ated at 125°C, 150 W for 5 min in the presence of sodium methoxide. 
Then, 2-bromo-1-(4-chlorophenyl)ethanone (1 mmol) was added and 
the mixture was irradiated in a MW reactor with pressure control 
at 150°C, 150  W for 20  min. Concentration under reduced pressure 
resulted in the formation of an orange solid that was treated with 
water, filtered off and crystallized from acetone.
1-(4-Chlorophenyl)-2-{3-[({3-fluoro-4-[4-(4-fluorophenyl)pip-
erazin-1-yl]phenyl}amino)methyl]-4-phenyl-5-thioxo-4,5-di-
hydro-1H-1,2,4-triazol-1-yl}ethanone (8a) Yield 35%, method 1, 
75%, method 2; mp 140–142°C; IR: νmax 3285 (NH), 3067 (aromatic 
CH), 1698 (C=O), 1508 (C=N), 1225 cm − 1 (C=S); 1H NMR: δ 2.95 (brs, 
4H, 2CH2), 3.17 (brs, 4H, 2CH2), 4.17 (s, 2H, CH2), 4.86 (s, 2H, CH2), 
5.91 (brs, 1H, NH), 6.98 (s, 5H, ArH), 7.46 (s, 8H, ArH), 8.01 (s, 3H, 
ArH); 13C NMR: δ 38.8 (CH2), 49.7 (CH2), 49.8 (2CH2), 50.9 (CH2), 51.5 
(CH2), Aryl-C: [101.0 and 101.2 (d, CH, J = 20  Hz), 108.5 (CH), 115.6 
and 115.8 (d, 2CH, J = 20  Hz), 117.7 and 117.8 (d, 2CH, J = 10  Hz), 
118.7 (CH), 127.5 (2CH), 129.4 (2CH), 130.0 (2CH), 130.3 (2CH), 130.4 
(CH), 133.2 (C), 134.5 (2C), 139.1 (2C), 145.2 (C), 148.3 and 154.2 (d, 
C, JC−F = 590 Hz), 150.6 and 155.4 (d, C, JC−F = 480 Hz)], 157.8 (triazole 
C-3 + triazole C-5), 192.7 (C=O); MS: m/z 655.30 ([M + 1 + Na] +, 32), 
654.36 ([M + Na] +, 46), 484.43 (89), 447.71 (48), 431.45 (100%). Anal. 
Calcd for C33H29ClF2N6OS: C, 62.80; H, 4.63; N, 13.32. Found: C, 62.66; 
H, 4.40; N, 13.61.
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4-Benzyl-3-[({3-fluoro-4-[4-(4-fluorophenyl)piperazin-1-yl]phe-
nyl}amino)methyl]-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-1-yl}-
1-(4-chlorophenyl)ethanone (8b) Yield: 32%, method 1), 52%, 
method 2; mp 190–192°C; IR: νmax 3377 (NH), 3000 (aromatic CH), 2955 
(aliphatic CH), 1683 (C=O), 1506 (C=N), 1226  cm − 1 (C=S); 1H NMR: δ 
2.99 (brs, 4H, 2CH2), 3.22 (brs, 6H, 3CH2), 5.33 (s, 4H, 2CH2), 6.17 (s, 3H, 
ArH), 6.73 (t, 2H, ArH, J = 8.0 Hz), 6.90–7.17 (m, 5H, ArH), 7.28–7.94 (m, 
6H, ArH), NH was not observed; 13C NMR: δ 47.2 (CH2), 49.7 (CH2), 49.9 
(2CH2), 51.5 (3CH2), Aryl-C: [108.5 (2CH), 115.6 and 115.7 (d, CH, J = 10 Hz), 
115.4 and 116.0 (d, 2CH, J = 20 Hz), 117.7 and 117.8 (d, 2CH, J = 10 Hz), 123.8 
(2CH), 126.0 (CH), 127.6 (2CH), 127.8 (2CH), 129.0 (2CH), 130.3 and 130.4 (d, 
2C, J = 10 Hz), 136.2 (C), 139.5 (2C), 144.8 and 144.9 (d, C, J = 10 Hz), 150.6 
and 155.4 (d, C, JC−F = 480 Hz), 155.5 and 157.7 (d, C, JC−F = 200 Hz)], 158.3 
(triazole C-3), 165.4 (triazole C-5), 185.3 (C=O); MS: m/z 646.89 ([M + 1] +, 
34), 458.00 (100), 234.09 (76%). Anal. Calcd for C34H31ClF2N6OS: C, 63.30; 
H, 4.84; N, 13.03. Found: C, 63.13; H, 5.00; N, 13.21.
1-(4-Chlorophenyl)-2-({4-ethyl-5-[({3-fluoro-4-[4-(4-fluorophe-
nyl)piperazin-1-yl]phenyl}amino)methyl]-4H-1,2,4-triazol-3-yl} 
thio)ethanone (8c) Yield 22%, method 1, 65%, method 2; mp 144–
147°C; IR: νmax 3370 (NH), 3054 (aromatic CH), 2951 (aliphatic CH), 
1692 (C=O), 1507 cm − 1 (C=N); 1H NMR: δ 1.10 (t, 3H, CH3, J = 6.4 Hz), 
2.99 (brs, 2H, CH2), 3.19 (brs, 8H, 4CH2), 4.02 (d, 2H, CH2, J = 6.8 Hz), 
4.38 (s, 2H, CH2), 4.92 (s, 1H, NH), 7.00–7.08 (m, 7H, ArH), 7.53 (d, 2H, 
ArH, J = 8.0 Hz), 7.61 (t, 1H, ArH, J = 7.6 Hz), 8.02 (d, 1H, ArH, J = 8.0 Hz); 
13C NMR: δ 15.4 (CH3), 49.8 (2CH2), 49.9 (2CH2), 50.8 (2CH2), 51.6 (CH2), 
Aryl-C: [100.9 (CH), 108.7 (CH), 115.7 and 115.9 (d, 2CH, J = 20 Hz), 117.8 
and 117.9 (d, 2CH, J = 10 Hz), 120.6 (CH), 129.4 (2CH), 130.8 (2CH), 134.5 
(2C), 139.1 (2C), 148.2 (C), 149.5 and 153.8 (d, 2C, JC−F = 430 Hz)], 155.5 
(triazole C-3 and triazole C-5), 192.8 (C=O); MS: m/z 583.21 ([M] +, 71), 
571.25 (47), 569.24 (100%). Anal. Calcd for C29H29ClF2N6OS: C, 59.73; H, 
5.01; N, 14.41. Found: C, 60.00; H, 5.09; N, 14.31.
General method for synthesis of compounds 9a–c
Method 1 Compound 8 (10  mmol) was stirred in the presence of 
NaBH4 (30 mmol) in absolute ethanol (40 mL) at room temperature for 
24 h (for 9a and 9c) or heated under reflux for 18 h (for 9b). Concen-
tration under reduced pressure resulted in the formation of a white 
solid that was washed with water and crystallized from acetone.
Method 2 A solution of compound 8 (1 mmol) and NaBH4 (3 mmol) 
in ethanol was irradiated at 100°C, 100 W for 20 min. Concentration 
under reduced pressure resulted in the formation of a white solid that 
was washed with water and crystallized from acetone.
2-[2-(4-Chlorophenyl)-2-hydroxyethyl]-5-[({3-fluoro-4-[4-(4-
fluorophenyl)piperazin-1-yl]phenyl}amino)methyl]-4-phenyl-
2,4-dihydro-3H-1,2,4-triazole-3-thione (9a) Yield 45%, method 
1, 75%, method 2; mp 153–155°C; IR: νmax 3298 (OH), 3049 (aromatic 
CH), 2920 (aliphatic CH), 1508 (C=N), 1223 cm − 1 (C=S); 1H NMR: δ 2.96 
(brs, 4H, 2CH2), 3.16 (brs, 4H, 2CH2), 3.22 (s, 2H, CH2), 4.17 (d, 2H, CH2, 
J = 8.0 Hz), 4.85 (q, 1H, CH, J = 4.4 Hz), 5.89 (brs, 1H, OH), 6.96–7.08 (m, 
7H, ArH), 7.29–7.45 (m, 6H, ArH), 7.56 (t, 3H, ArH, J = 4.0 Hz), signal for 
NH was not observed; 13C NMR: δ 38.8 (CH2), 41.0 (CH2), 49.7 (CH2), 
49.8 (CH2), 51.0 (CH2), 51.5 (CH2), 70.7 (CH), Aryl-C: [101.0 and 101.2 (d, 
CH, J = 20 Hz), 106.9 and 107.2 (d, CH, J = 30 Hz), 108.5 (CH), 115.8 and 
115.9 (d, 2CH, J = 10 Hz), 117.7 and 117.8 (d, 2CH, J = 10 Hz), 127.6 (2CH), 
128.3 (2CH), 128.5 (CH), 130.3 (2CH), 130.4 (2CH), 130.0 and 130.1 (d, C, 
J = 10 Hz), 132.2 (C), 133.3 (C), 143.2 (C), 145.2 and 145.3 (d, C, J = 10 Hz), 
148.3 and 148.4 (d, C, J= 10 Hz), 151.6 and 155.4 (d, C, JC−F = 380 Hz), 
152.9 and 157.7 (d, C, JC−F = 480 Hz)], 154.1 (triazole C-3), 155.4 (triazole 
C-5); MS: m/z 657.13 ([M + 2 + Na] +, 51), 655.18 ([M + Na] +, 100%). Anal. 
Calcd for C33H31ClF2N6OS: C, 62.60; H, 4.94; N, 13.27. Found: C, 62.50; 
H, 5.04; N, 13.31.
4-Benzyl-2-[2-(4-chlorophenyl)-2-hydroxyethyl]-5-[({3-fluoro-
4-[4-(4-fluorophenyl)piperazin-1-yl]phenyl}amino)methyl]-
2,4-dihydro-3H-1,2,4-triazole-3-thione (9b) Yield 48%, method 
1, 68%, method 2; mp 180–182°C; IR: νmax 3357 (OH), 3025 (aromatic 
CH), 3122 (NH), 2953 (aliphatic CH), 1505 (C=N), 1235 cm − 1 (C=S); 1H 
NMR: δ 3.11 (s, 2H, CH2), 3.12 (brs, 4H, 2CH2), 3.18 (brs, 4H, 2CH2), 
3.34 (s, 4H, 2CH2), 5.05 (s, 1H, CH), 6.35 (brs, 1H, OH), 6.75–6.78 (m, 
2H, ArH), 6.99–7.09 (m, 5H, ArH), 7.19–7.37 (m, 7H, ArH), 7.41–7.51 (m, 
2H, ArH), 9.07 (brs, 1H, NH); 13C NMR: δ 40.6 (2CH2), 44.1 (2CH2), 50.1 
(3CH2), 70.1 (CH), Aryl-C: [106.2 (2CH), 108.2 (2CH), 110.2 (2CH), 116.8 
and 116.9 (d, 2CH, J = 10  Hz), 118.43 and 118.54 (d, 2CH, J = 11  Hz), 
120.2 (CH), 125.5 (CH), 127.8 (CH), 129.3 (2CH), 130.0 (CH), 132.4 
(2C), 133.8 (2C), 135.2 and 135.4 (d, 2C, J = 20 Hz), 151.6 and 154.4 (d, 
2C, JC−F = 280  Hz)], 155.2 (triazole C-3), 162.7 (triazole C-5); MS: m/z 
671.31 ([M + 1 + K] +, 28), 605.17 (100), 555.21 (35%). Anal. Calcd for 




3-yl}thio)ethanol (9c) Yield 40%, method 1, 71%, method 2); mp 
166–168°C; IR: νmax 3321 (OH), 3051 (aromatic CH), 2953 (aliphatic 
CH), 1507 cm − 1 (C=N); 1H NMR: δ 1.23 (brs, 3H, CH3), 2.97 (brs, 2H, 
CH2), 3.12 (brs, 2H, CH2), 3.18 (s, 2H, CH2), 3.23 (s, 2H, CH2), 3.34 (s, 
4H, 2CH2), 3.94 (s, 2H, CH2), 4.37 (s, 1H, CH), 4.88 (brs, 1H, OH), 6.26 
(s, 1H, NH), 6.80 (d, 1H, ArH, J = 8.0  Hz), 7.00–7.07 (m, 6H, ArH), 
7.39–7.52 (m, 2H, ArH), 7.58 (d, 2H, ArH, J = 7.6 Hz); 13C NMR: δ 15.4 
(CH3), 49.7 (CH2), 49.8 (2CH2), 50.9 (2CH2), 51.5 (2CH2), 70.8 (CH), 
Aryl-C: [100.9 and 101.2 (d, CH, J = 30  Hz), 108.6 (CH), 109.5 and 
109.7 (d, CH, J = 20 Hz), 115.6 and 115.8 (d, 2CH, J = 20 Hz), 117.7 and 
117.8 (d, 2CH, J = 30  Hz), 128.4 (2CH), 128.5 (2CH), 130.5 (C), 132.2 
(2C), 134.5 (C), 138.8 (C), 143.2 and 148.3 (d, C, JC−F = 510 Hz), 150.4 
and 153.6 (d, C, JC−F = 320  Hz)], 153.4 (triazole C-3), 158.9 (triazole 
C-5); MS: m/z 609.20 ([M + 1 + Na] +, 56), 607.25 (100%). Anal. Calcd 
for C29H31ClF2N6OS: C, 59.53; H, 5.34; N, 14.36. Found: C, 59.67; H, 
5.16; N, 14.01.
General method for synthesis of compounds 10a–i
Method 1 NaH (10  mmol) was added to a solution of compound 
9 (10 mmol) in tetrahydrofuran and the mixture was heated under 
reflux for 6  h. Then, the corresponding benzyl chloride was added 
and the mixture was heated under reflux for an additional 8–12  h. 
After concentration under reduced pressure, the resultant oily mass 
was treated with K2CO3 (10  mmol) solution and the mixture was 
extracted with ethyl acetate (3 × 15 mL). The organic layer was dried 
with Na2SO4 and concentrated under reduced pressure. The residue 
was crystallized from acetone (10a–d, 10g) or purified by silica gel 
column chromatography eluting with ethyl acetate/n-hexane (3 : 7, 
10e, 10f, 10h, 10i).
50      S. Basoglu Ozdemir et al.: New piperazine based heterocyclic compounds
Method 2 NaH (1  mmol) was added to a solution of compound 9 
(1  mmol) in THF (10  mL) and the mixture was irradiated at 80°C, 
100 W for 10 min. Then, the corresponding benzyl chloride (3 mmol) 
was added, and heating was continued for 20  min at 100°C at 150 
W. After concentration the crude product was treated with K2CO3 
(10 mmol) solution and the mixture was extracted with ethyl acetate 
(3 × 15  mL). The extract was dried with Na2SO4, concentrated under 
a reduced pressure and the residue was crystallized from acetone 
(10a–d, 10g) or purified by silica gel column chromatography elut-




compound was obtained from 9a and 4-chlorobenzyl chloride; yield 
25%, method 1, 70%, method 2; mp 58–60°C; IR: νmax, cm − 1): 3263 
(NH), 3056 (aromatic CH), 2919 (aliphatic CH), 1507 (C=N), 1227 (C=S), 
1089 cm − 1 (C-O); 1H NMR: δ 3.04 (brs, 4H, 2CH2), 3.24 (brs, 6H, 3CH2), 
3.46 (s, 2H, CH2), 4.19 (s, 2H, CH2), 4.76 (brs, 1H, CH), 6.87–6.94 (m, 
1H, ArH), 7.09 (s, 5H, ArH), 7.38–7.56 (m, 11H, ArH), 7.57 (d, 3H, ArH, 
J = 7.2  Hz), NH was not observed; 13C NMR: δ 40.6 (CH2), 41.0 (CH2), 
45.6 (CH2), 50.1 (CH2), 50.8 (CH2), 51.5 (CH2), 62.6 (CH2), 70.7 (CH), Aryl-
C: [100.9 and 101.2 (d, CH, J = 20 Hz), 108.6 (CH), 115.8 and 116.0 (d, 
CH, J = 20 Hz), 118.5 (2CH), 127.6 (CH), 128.3 (2CH), 128.4 (2CH), 128.5 
(CH), 128.6 (CH), 128.8 (CH), 128.9 (CH), 129.1 (CH), 129.1 (CH), 129.2 
(2CH), 130.3 (2CH), 130.4 (C), 131.2 (C), 132.2 (2C), 137.2 (C), 137.7 (C), 
143.2 (2C), 151.8 and 153.4 (d, C, JC−F = 160 Hz), 151.9 and 154.0 (d, C, 
JC−F = 210 Hz)], 155.4 (triazole C-3), 157.8 (triazole C-5); MS: m/z 780.21 
([M + Na] +, 24), 612.09 (54), 555.90 (15), 498.00 (100%). Anal. Calcd 





(10b) This compound was obtained from 9a and 2,4-chlorobenzyl 
chloride; yield 32%, method 1, 55%, method 2; mp 150–152°C; IR: 
νmax 3263 (NH), 3066 (aromatic CH), 2917 (aliphatic CH), 1507 (C=N), 
1227 (C=S), 1144 cm − 1 (C-O); 1H NMR: δ 2.50 (s, 2H, CH2), 2.97 (s, 2H, 
CH2), 3.18 (brs, 4H, 2CH2), 3.36 (brs, 4H, 2CH2), 4.17 (s, 2H, CH2), 4.85 
(t, 1H, CH, J = 7.2 Hz), 6.30 (d, 1H, ArH, J = 8.4 Hz), 6.41 (s, 5H, ArH), 
6.83 (t, 2H, ArH, J = 8.8 Hz), 6.99–7.43 (m, 7H, ArH), 7.56 (s, 4H, ArH), 
8.98 (brs, 1H, NH); 13C NMR: δ 40.6 (CH2), 40.9 (CH2), 44.8 (CH2), 49.9 
(CH2), 50.2 (CH2), 51.5 (2CH2), 70.7 (CH), Aryl-C: [101.0 and 101.2 (d, CH, 
J = 20 Hz), 108.5 (CH), 115.6 and 115.8 (d, 2CH, J = 20 Hz), 117.8 and 117.9 
(d, 2CH, J = 20 Hz), 121.0 (2CH), 127.6 (2CH), 128.3 (2CH), 128.5 (2CH), 
128.6 (CH), 130.3 (2CH), 130.4 (2CH), 132.2 (2C), 133.3 (2C), 141.3 (2C), 
143.2 (2C), 145.5 (C), 154.1 and 157.7 (d, 2C, JC−F = 360 Hz)], 151.6 (tria-
zole C-3), 157.9 (triazole C-5); MS: m/z 793.45 ([M + 1] +, 56), 605.25 (68), 
551.21 (20), 321.98 (100%). Anal. Calcd for C40H35Cl3F2N6OS: C, 60.65; 




(10c) This compound was obtained from 9a and 2,6-chlorobenzyl 
chloride; yield 24%, method 1, 58%, method 2; mp 126–127°C; IR: 
νmax 3083 (aromatic CH), 2956 (aliphatic CH), 1508 (C=N), 1226 (C=S), 
1091 cm − 1 (C-O); 1H NMR: δ 3.17 (brs, 4H, 2CH2), 3.28 (brs, 4H, 2CH2), 
4.84 (s, 7H, 3CH2 + CH), 7.09 (brs, 4H, ArH), 7.27–7.34 (m, 6H, ArH), 
7.34–7.54 (m, 9H, ArH), 8.98 (brs, 1H, NH); 13C NMR: δ 41.3 (2CH2), 
58.8 (2CH2), 60.2 (3CH2), 70.3 (CH), Aryl-C: [108.2 and 108.4 (d, CH, 
J = 20  Hz), 116.2 (2CH), 117.2 and 117.4 (d, 2CH, J = 20  Hz), 118.3 and 
118.4 (d, 2CH, J = 10  Hz), 128.4 (CH), 128.5 (CH), 128.8 (CH), 128.9 
(CH), 129.1 (CH), 129.6 (CH), 129.7 (2CH), 130.3 (2CH), 131.6 (2CH), 133.2 
(2C), 135.6 (2C), 136.0 (2C), 136.5 (2C), 136.7 (C), 152.1 and 155.2 (d, 2C, 
JC−F  = 31.0 Hz)], 157.6 (triazole C-2), 161.1 (triazole C-5); MS: m/z 810.90 
([M + H2O] +, 12), 456.90 (100%). Anal. Calcd for C40H35Cl3F2N6OS: C, 




(10d) This compound was obtained from 9b and 4-chlorobenzyl 
chloride; yield 31%, method 1, 55%, method 2; mp 42–44°C; IR: 
νmax 3120 (NH), 3092 (aromatic CH), 2918 (aliphatic CH), 1588 (C=N), 
1237 cm − 1 (C=S); 1H NMR: δ 3.11 (brs, 4H, 2CH2), 3.21 (brs, 4H, 2CH2), 
3.40 (s, 6H, 3CH2), 4.40 (brs, 1H, CH), 5.05 (s, 2H, CH2), 6.37 (s, 1H, 
ArH), 6.75–6.78 (m, 2H, ArH), 7.06–7.09 (m, 8H, ArH), 7.21–7.29 (m, 5H, 
ArH), 7.34 (d, 2H, ArH, J = 8.0 Hz), 7.47 (d, 2H, ArH, J = 8.0 Hz), 11.10 
(s, 1H, NH); 13C NMR: δ 48.2 (2CH2), 49.7 (3CH2), 51.0 (3CH2), 90.9 (CH), 
Aryl-C: [109.4 and 109.5 (d, CH, J= 10 Hz), 111.2 (CH), 115.7 and 115.8 
(d, 2CH, J = 10 Hz), 117.2 and 117.3 (d, 2CH, J = 10 Hz), 117.8 and 117.9 (d, 
CH, J = 10 Hz), 119.2 (2CH), 126.9 (2CH), 127.5 (2CH), 128.5 (2CH), 128.9 
(CH), 129.2 (2CH), 130.2 (C), 130.9 (2CH), 134.5 (2C), 136.8 (2C), 137.6 
(2C), 138.8 (C), 139.9 (C), 140.1 (C)], 148.3 (triazole C-3), 159.6 (triazole 
C-5); MS: m/z 732.19 (9), 461.27 (100), 177.90 (52%). Anal. Calcd for 





(10e) This compound was obtained from 9b and 2,4-dichlorobenzyl 
chloride; yield 30%, method 1, 55%, method 2; yellow oil; IR: νmax 
3092 (aromatic CH), 2963 (aliphatic CH), 1588 (C=N), 1508 (C=N), 
1228  cm − 1 (C=S); 1H NMR: δ 2.50 (brs, 4H, 2CH2), 3.04 (s, 2H, CH2), 
3.24 (brs, 4H, 2CH2), 3.43 (s, 4H, 2CH2), 4.81 (brs, 3H, CH + CH2), 7.08 
(brs, 3H, ArH), 7.31–7.37 (m, 5H, ArH), 7.46–7.48 (m, 5H, ArH), 7.64–7.68 
(m, 6H, ArH), 9.12 (brs, 1H, NH); 13C NMR: δ 40.6 (3CH2), 43.3 (3CH2), 
49.9 (2CH2), 60.2 (CH), Aryl-C: [116.5 (2CH), 126.9 (2CH), 127.1 (2CH), 
127.6 (CH), 128.2 and 128.3 (d, CH, J = 10 Hz), 128.5 (CH), 128.6 (CH), 
129.1 (2CH), 129.2 (2CH), 129.4 (2CH), 129.7 (2CH), 129.8 (CH), 131.9 (C), 
132.2 (2C), 132.3 (C), 133.3 (C), 134.5 and 134.9 (d, 2C, J = 40 Hz), 136.7 
(C), 139.3 (C), 150.4 and 154.2 (d, 2C, JC−F =380 Hz)], 153.6 (triazole C-3), 





compound was obtained from 9b and 2,6-chlorobenzyl chloride; yield 
42%, method 1, 67%, method 2, yellow oil; IR: νmax 3063 (aromatic CH), 
2924 (aliphatic CH), 1508 (C=N), 1226 cm − 1 (C=S); 1H NMR: δ 3.03 (brs, 
4H, 2CH2), 3.13 (brs, 4H, 2CH2), 3.22 (s, 4H, 2CH2), 3.39–3.45 (m, 2H, 
CH2), 4.90 (s, 3H, CH + CH2), 7.03–7.08 (m, 5H, ArH), 7.27–7.42 (m, 7H, 
ArH), 7.50–7.55 (m, 7H, ArH), 9.24 (brs, 1H, NH); 13C NMR: δ 40.4 (3CH2), 
41.4 (3CH2), 50.1 (2CH2), 58.7 (CH), Aryl-C: [116.3 (CH), 126.9 (2CH), 127.0 
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(2CH), 127.4 (CH), 128.2 and 128.4 (d, 2CH, J = 20 Hz), 128.5 (CH), 128.9 
(CH), 128.9 (CH), 129.9 (CH), 129.1 (2CH), 129.2 (2CH), 129.3 (2CH), 130.6 
(CH), 131.6 (C), 131.9 (C), 133.3 (2C), 135.6 (2C), 135.9 (2C), 136.7 (C), 152.2 
and 156.2 (d, 2C, JC−F = 400 Hz)], 155.2 (triazole C-3), 162.7 (triazole C-5); 
MS: m/z 824.56 ([M + H2O] +, 34), 778.09 (100%).
N-[(5-{[2-(4-Chlorophenoxy)-2-(4-chlorophenyl)ethyl]thio}-4-
ethyl-4H-1,2,4-triazol-3-yl)methyl]-3-fluoro-4-[4-(4-fluorophe-
nyl)piperazin-1-yl]aniline (10g) This compound was obtained 
from 9c and 4-chlorobenzyl chloride; yield 33%, method 1, 66%, 
method 2; mp 94–95°C; IR: νmax 3407 (NH), 3056 (aromatic CH), 2955 
(aliphatic CH), 1507 cm − 1 (C=N); 1H NMR: δ 1.18 (brs, 3H, CH3), 2.98 (s, 
2H, CH2), 3.05 (brs, 4H, 2CH2), 3.13–3.19 (m, 4H, 2CH2), 3.20 (brs, 4H, 
2CH2), 3.98 (q, 2H, CH2, J = 6.8 Hz), 4.79 (s, 1H, CH), 6.59–6.99 (m, 3H, 
ArH), 7.00–7.07 (m, 5H, ArH), 7.08 (d, 4H, ArH, J = 5.2 Hz), 7.38 (d, 3H, 
ArH, J = 9.6 Hz), 10.42 (brs, 1H, NH); 13C NMR: δ 14.0 (CH3), 34.4 (CH2), 
49.7 (2CH2), 49.8 (CH2), 49.9 (CH2), 50.8 (CH2), 51.2 (CH2), 63.9 (CH2), 70.8 
(CH), Aryl-C: [105.6 and 105.8 (d, CH, J = 20 Hz), 109.1 (CH), 113.6 (CH), 
115.7 and 115.9 (d, 2CH, J = 20 Hz), 117.8 and 117.9 (d, 2CH, J = 10 Hz), 
119.7 (2CH), 120.9 (CH), 128.4 (CH), 128.5 (CH), 128.7 (CH), 128.9 (CH), 
129.5 (CH), 130.1 (C), 133.8 (2C), 136.9 (2C), 148.2 (2C), 154.9 and 157.8 
(d, C, JC−F =  = 290 Hz), 155.5 and 157.3 (d, C, JC−F = 180 Hz)], 161.6 (tria-
zole C-3), 164.7 (triazole C-5); MS: m/z 710.65 ([M + 1] +, 56), 651.20 (43), 
600.21 (100), 554.32 (13%). Anal. Calcd for C36H36Cl2F2N6OS: C, 60.93; 
H, 5.11; N, 11.84. Found: C, 60.88; H, 5.31; N, 11.91.
N-[(5-{[2-(4-Chlorophenyl)-2-(2,4-dichlorophenoxy)ethyl]thio}-
4-ethyl-4H-1,2,4-triazol-3-yl)methyl]-3-fluoro-4-[4-(4-fluorophe-
nyl)piperazin-1-yl]aniline (10h) This compound was obtained 
from 9c and 2,4-chlorobenzyl chloride; yield 39%, method 1, 51%, 
method 2; brown oil; IR: νmax 3063 (aromatic CH), 2925 (aliphatic CH), 
1508 (C=N), 1098 cm − 1 (C-O); 1H NMR: δ 1.06 (brs, 3H, CH3), 3.10 (brs, 
4H, 2CH2), 3.26 (brs, 4H, 2CH2), 4.77 (s, 9H, 4CH2 + CH), 7.08 (s, 4H, 
ArH), 7.39–7.41 (m, 5H, ArH), 7.59 (t, 5H, ArH, J = 8.4  Hz), 9.65 (brs, 
1H, NH); 13C NMR: δ 18.9 (CH3), 43.3 (CH2), 49.9 (CH2), 52.3 (2CH2), 56.5 
(2CH2), 60.2 (2CH2), 70.7 (CH), Aryl-C: [116.2 and 116.4 (d, CH, J = 20 Hz), 
127.5 (2CH), 128.2 (2CH), 128.5 and 128.6 (d, CH, J = 10 Hz), 128.9 (2CH), 
129.6 and 129.7 (d, 2CH, J = 10  Hz), 131.3 (CH), 131.5 (CH), 132.2 (C), 
132.3 (C), 133.2 (2CH), 134.6 (2C), 134.7 (C), 134.8 (2C), 139.3 (C), 154.3 
and 157.2 (d, C, JC−F = 290 Hz), 156.2 and 157.8 (d, C, JC−F = 160 Hz)], 160.2 
(triazole C-3), 165.0 (triazole C-5); MS: m/z 744.90 ([M] +, 23), 701.26 
(100), 556.09 (67), 501.21 (43%).
N-[(5-{[2-(4-Chlorophenyl)-2-(2,6-dichlorophenoxy)ethyl]thio}-
4-ethyl-4H-1,2,4-triazol-3-yl)methyl]-3-fluoro-4-[4-(4-fluorophe-
nyl)piperazin-1-yl]aniline (10i) This compound was obtained 
from 9c and 2,6-chlorobenzyl chloride; yield 44%, method 1), 62%, 
method 2; brown oil; IR: νmax 3056 (aromatic CH), 2924 (aliphatic 
CH), 1508 (C=N), 1091 cm − 1 (C-O); 1H NMR: δ 1.04–1.06 (m, 3H, CH3), 
3.27 (brs, 8H, 4CH2), 4.36 (brs, 6H, 3CH2), 4.85 (brs, 3H, CH2 + CH), 
7.37–7.53 (m, 14H, ArH), 9.02 (brs, 1H, NH); 13C NMR: δ 15.9 (CH3), 43.7 
(2CH2), 49.9 (2CH2), 50.2 (CH2), 51.8 (CH2), 58.7 (2CH2), 101.0 (CH), Aryl-
C: [108.5 (CH), 116.1 (CH), 116.2 (CH), 116.3 (2CH), 119.9 (CH), 128.9 
(2CH), 129.1 (2CH), 129.2 (2CH), 129.3 (2CH), 130.6 (2C), 130.8 (C), 131.9 
(2C), 133.3 (C), 135.6 (C), 136.1 (C), 153.6 and 155.5 (d, 2C, JC−F= 190 Hz)], 
157.9 (triazole C-3), 164.7 (triazole C-5); MS: m/z 767.23 ([M + Na] +, 24), 
420.00 (100), 389.92 (75%).
General method for synthesis of compounds 11–14
Method 1 To a solution of corresponding compound 7 (10  mmol) 
in DMF containing HCl (50% mmol), norfloxacin (for 11a–c), cipro-
floxacin (for 12a–c), thiomorpholine (for 13a,b) or phenylpiperazine 
(for 14) (10 mmol) was added and the mixture was stirred at room 
temperature in the presence of formaldehyde (50 mmol) for 24 h. The 
solid obtained was collected by filtration, washed with water and 
crystallized from DMSO/water (1 : 3).
Method 2 A solution of 7 (1 mmol), norfloxacin (for 11a–c), cipro-
floxacin (for 12a–c), thiomorpholine (for 13a,b) or phenylpiperazine 
(for 14) (1 mmol), HCl (50% mmol) and formaldehyde (5 mmol) was 
irradiated in a MW reactor with pressure control at 50°C, 70  W for 





1,4-dihydroquinoline-3-carboxylic acid (11a) This compound 
was obtained from 7a and norfloxacin; yield 56%, method 1, 83%, 
method 2; mp 103–105°C; IR: νmax 3359 (OH), 3060 (aromatic CH), 
2920 (aliphatic CH), 1710 (C=O), 1659 (C=O), 1508 (C=N), 1226  cm − 1 
(C=S); 1H NMR: δ 1.41 (brs, 3H, CH3), 2.50 (s, 2H, CH2), 2.73 (s, 2H, CH2), 
2.89 (s, 2H, CH2), 3.00 (brs, 4H, 2CH2), 3.37 (brs, 8H, 4CH2), 4.14 (s, 
2H, CH2), 4.58 (s, 2H, CH2), 6.99–7.03 (m, 7H, ArH), 7.20 (brs, 2H, ArH), 
7.32 (s, 1H, ArH), 7.44 (s, 2H, ArH), 7.56 (s, 2H, ArH), 7.95 (s, 1H, ArH), 
8.95 (s, 1H, quinolone CH), 15.36 (s, 1H, OH); 13C NMR: δ 14.8 (CH3), 
31.2 (CH2), 47.9 (CH2), 49.4 (CH2), 49.6 (CH2), 49.7 (CH2), 49.8 (CH2), 50.7 
(CH2), 51.1 (CH2), 51.3 (CH2), 51.5 (2CH2), 107.5 (C), Aryl-C: [106.2 (CH), 
111.6 and 111.8 (d, CH, J = 20  Hz), 115.6 and 115.9 (d, CH, J = 30  Hz), 
117.4 and 117.5 (d, 2CH, J = 10 Hz), 117.8 and 117.9 (d, 2CH, J = 10 Hz), 
118.9 (CH), 119.7 (C), 121.9 (CH), 128.5 (CH), 129.3 (2CH), 129.9 (2CH), 
134.4 (C), 134.7 (C), 136.2 (C), 136.3 (2C), 137.6 (C), 141.4 (C), 147.1 (C), 
149.3 (C)], 149.0 (CH), 162.8 (triazole C-3), 166.6 (triazole C-5), 176.6 and 
181.7 2(C=O); MS: m/z 680.45 (26), 386.38 (25), 288.27 (100%). Anal. 





quinoline-3-carboxylic acid (11b) This compound was obtained 
from 7b and norfloxacin; yield 45%, method 1), 82%, method 2; mp 
204–206°C; IR: νmax 3307 (OH), 3065 (aromatic CH), 2920 (aliphatic 
CH), 1723 (C=O), 1668 (C=O), 1507 (C=N), 1226  cm − 1 (C=S); 1H NMR: 
δ 1.37 (t, 3H, CH3, J = 6.8 Hz), 2.50 (s, 2H, CH2), 2.70 (s, 2H, CH2), 2.81 
(brs, 4H, 2CH2), 3.13 (brs, 2H, CH2), 3.18 (brs, 2H, CH2), 3.22 (s, 2H, CH2), 
3.26 (s, 2H, CH2), 3.35 (s, 2H, CH2), 4.56 (s, 2H, CH2), 5.20 (s, 2H, CH2), 
5.39 (s, 2H, CH2), 6.28 (brs, 1H, NH), 6.67–6.76 (m, 2H, ArH), 6.92–7.07 
(m, 5H, ArH), 7.27–7.33 (m, 6H, ArH), 7.91 (s, 1H, ArH), 8.90 (s, 1H, qui-
nolone CH), 15.31 (brs, 1H, OH); 13C NMR: δ 14.8 (CH3), 47.2 (CH2), 48.4 
(CH2), 49.5 (CH2), 49.7 (2CH2), 50.0 (2CH2), 50.7 (2CH2), 51.2 (2CH2), 68.8 
(CH2), 107.6 (C), Aryl-C: [106.3 (CH), 108.7 (CH), 111.5 and 111.7 (d, CH, 
J = 20 Hz), 115.4 and 115.6 (d, CH, J = 20 Hz), 115.9 (CH), 117.3 and 117.4 
(d, 2CH, J = 10 Hz), 117.8 and 117.9 (d, 2CH, J = 10 Hz), 119.5 and 119.7 (d, 
C, J = 20 Hz), 127.9 (CH), 128.7 (2CH), 129.01 (2CH), 130.4 (C), 135.9 (C), 
137.6 (C), 139.4 (C), 144.3 (C), 148.1 and 148.3 (d, C, J = 20 Hz), 146.1 and 
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154.6 (d, C, JC−F = 850 Hz), 149.3 and 155.3 (d, C, JC−F = 600 Hz), 152.2 and 
157.6 (d, C, JC−F = 540 Hz)], 148.8 (CH), 166.5 (triazole C-3), 169.3 (triazole 
C-5), 176.6 (C=O), 181.3 (C=O); MS: m/z 824.48 ([M + 1] +, 10), 798.39 (15), 
776.62 (19), 749.40 (25), 739.51 (28), 724.50 (53), 723.49 (100), 718.64 
(65%). Anal. Calcd for C43H44F3N9O3S: C, 62.68; H, 5.38; N, 15.30. Found: 




quinoline-3-carboxylic acid (11c) This compound was obtained 
from 7c and norfloxacin; yield 47%, method 1, 77%, method 2); mp 
152–154°C; IR: νmax 3500 (OH), 3060 (aromatic CH), 2944 (aliphatic 
CH), 1724 (C=O), 1666 (C=O), 1508 (C=N), 1235 cm − 1 (C=S); 1H NMR: δ 
1.22 (brs, 3H, CH3), 1.39 (brs, 3H, CH3), 2.73 (brs, 6H, 3CH2), 3.01 (brs, 
6H, 3CH2), 3.19 (brs, 8H, 4CH2), 4.06 (s, 2H, CH2), 4.58 (s, 2H, CH2), 
5.14 (brs, 1H, NH), 7.05 (brs, 8H, ArH), 7.95 (s, 1H, ArH), 8.96 (s, 1H, 
quinolone CH), 15.33 (s, 1H, OH); 13C NMR: δ 13.5 (CH3), 14.8 (CH3), 
36.2 (CH2), 39.3 (CH2), 48.4 (CH2), 49.5 (CH2), 49.7 (CH2), 49.8 (CH2), 50.0 
(CH2), 50.8 (CH2), 51.1 (CH2), 51.2 (2CH2), 79.9 (CH2), 107.6 (C), Aryl-C: 
[106.4 (CH), 111.5 and 111.7 (d, CH, J = 20 Hz), 113.5 (CH), 115.5 (CH), 
115.6 and 115.8 (d, 2CH, J = 20 Hz), 117.3 and 117.4 (d, 2CH, J = 10 Hz), 
117.8 and 117.9 (d, C, J = 10 Hz), 120.2 (CH), 129.4 (C), 133.1 (C), 136.4 (C), 
137.6 (C), 144.8 (C), 149.1 and 155.4 (d, C, JC−F = 630 Hz), 153.4 and 157.2 
(d, C, JC−F = 380 Hz), 154.7 and 157.77(d, 2C, JC−F = 300 Hz)], 148.9 (CH), 
162.1 (triazole C-3), 166.5 (C=O), 166.6 (C=O), 168.2 (triazole C-5); MS: 
m/z 785.25 ([M + 1 + Na] +, 56), 784.25 ([M + Na] +, 84), 763.16 ([M + 2] +, 
42), 762.35 ([M + 1] +, 85), 750.46 (43), 749.21 (100%). Anal. Calcd for 





hydroquinoline-3-carboxylic acid (12a) This compound was 
obtained from 7a and ciprofloxacin; yield 56%, method 1), 89%, 
method 2; mp 115–117°C; IR: νmax 3356 (OH), 3065 (aromatic CH), 2949 
(aliphatic CH), 1714 (C=O), 1659 (C=O), 1507 (C=N), 1224 cm − 1 (C=S); 
1H NMR: δ 1.18 (s, 2H, CH2), 1.32 (s, 2H, CH2), 2.73 (brs, 4H, 2CH2), 3.00 
(brs, 6H, 3CH2), 3.14 (s, 2H, CH2), 3.17 (brs, 4H, 2CH2), 3.80 (brs, 1H, 
CH), 4.16 (s, 2H, CH2), 5.21 (s, 2H, CH2), 5.81 (brs, 1H, NH), 6.77 (brs, 
1H, ArH), 7.01–7.07 (m, 6H, ArH), 7.33 (s, 1H, ArH), 7.46 (s, 3H, ArH), 
7.56 (s, 2H, ArH), 7.90 (s, 1H, ArH), 8.65 (s, 1H, quinolone CH), 15.22 
(s, 1H, OH); 13C NMR: δ 8.1 (2CH2), 36.2 (CH), 47.9 (CH2), 49.2 (CH2), 
49.6 (CH2), 49.7 (CH2), 49.8 (CH2), 49.9 (CH2), 50.7 (CH2), 51.1 (CH2), 51.3 
(CH2), 51.5 (CH2), 107.2 (C), Aryl-C: [106.6 and 106.8 (d, CH, J = 20 Hz), 
111.4 and 111.6 (d, CH, J = 20 Hz), 115.6 and 115.7 (d, CH, J = 10 Hz), 
115.8 and 115.9 (d, 2CH, J = 10 Hz), 117.7 and 117.8 (d, 2CH, J = 10 Hz), 
121.9 (CH), 125.7 (CH), 128.9 (2CH), 129.4 (2CH), 129.9 (CH), 134.4 (C), 
136.6 and 136.9 (d, C, J = 30 Hz), 139.6 and 139.7 (d, C, J = 10 Hz), 141.4 
(C), 144.5 (C), 145.1 and 145.7 (d, C, J = 60 Hz), 148.1 and 148.3 (d, C, 
J = 20 Hz), 151.9 and 154.8 (d, C, JC−F = 290 Hz), 152.3 and 155.5 (d, C, 
JC−F = 320 Hz), 154.5 and 157.8 (d, C, JC−F  = 330 Hz)], 148.5 (CH), 162.8 
(triazole C-3), 169.6 (triazole C-5), 176.8 and 181.8 2(C=O); MS: m/z 
844.31 ([M + Na] +, 79), 840.62 (56), 830.36 (79), 828.61 (55), 821.98 
([M] +, 100), 815.85 (49), 811.40 (60), 804.15 (43), 794.38 (48%). Anal. 
Calcd for C43H42F3N9O3S: C, 62.84; H, 5.15; N, 15.34. Found: C, 62.60; 




hydroquinoline-3-carboxylic acid (12b) This compound was 
obtained from 7b and ciprofloxacin; yield 50%, method 1, 90%, 
method 2; mp 170–172°C; IR: νmax 3297 (OH), 3065 (aromatic CH), 2919 
(aliphatic CH), 1721 (C=O) and 1667 (C=O), 1508 (C=N), 1225 cm − 1 (C=S); 
1H NMR: δ 1.08 (s, 2H, CH2), 1.18 (s, 2H, CH2), 2.73 (brs, 4H, 2CH2), 2.89 
(brs, 4H, 2CH2), 3.22 (brs, 4H, 2CH2), 3.34 (brs, 6H, 3CH2), 3.79 (brs, 1H, 
CH), 5.20 (s, 2H, CH2), 5.39 (s, 2H, CH2), 6.73–6.77 (m, 1H, ArH), 6.94–
7.07 (m, 5H, ArH), 7.34 (brs, 7H, ArH), 7.93 (s, 1H, ArH), 8.65 (s, 1H, qui-
nolone CH), 9.26 (brs, 1H, NH), 15.15 (s, 1H, OH); 13C NMR: δ 8.0 (2CH2), 
36.2 (CH), 47.2 (CH2), 48.4 (CH2), 49.5 (CH2), 49.7 (CH2), 49.8 (CH2), 49.9 
(CH2), 50.7 (CH2), 51.1 (CH2), 51.3 (2CH2), 68.7 (CH2), 107.3 (C), Aryl-C: 
[106.8 (CH), 108.7 (CH), 111.3 and 111.5 (d, CH, J = 20 Hz), 115.5 and 115.7 
(d, CH, J = 20 Hz), 117.3 and 117.4 (d, 2CH, J= 10 Hz), 117.8 and 117.9 (d, 
2CH, J = 10 Hz), 119.1 (C), 120.6 (CH), 127.9 (2CH), 128.7 (2CH), 129.1 (CH), 
130.4 (C), 135.9 (2C), 139.4 and 139.5 (d, C, J = 10 Hz), 144.4 (C), 145.8 
and 149.4 (d, C, JC−F = 360 Hz), 148.0 and 148.2 (d, C, J = 20 Hz), 152.0 
and 155.3 (d, C, JC−F = 330 Hz), 154.8 and 157.7 (d, C, JC−F  = 290 Hz)], 148.3 
(CH), 166.2 (triazole C-3), 169.4 (triazole C-5), 176.7 and 181.3 2(C=O); 
MS: m/z 868.34 (52), 858.39 ([M + Na] +, 35), 850.63 (32), 849.63 (28), 
837.43 ([M + 2] +, 50), 836.31 ([M + 1] +,100), 827.42 (31%). Anal. Calcd for 





hydroquinoline-3-carboxylic acid (12c) This compound was 
obtained from 7c and ciprofloxacin; yield 78%, method 1, 94%, 
method 2); mp 192–194°C; IR: νmax 3400 (OH), 3061 (aromatic CH), 
2925 (aliphatic CH), 1628 (2C=O), 1507 (C=N), 1217  cm − 1 (C=S); 1H 
NMR: δ 1.17 (brs, 5H, CH3 + CH2), 1.31 (s, 2H, CH2), 2.25 (s, 2H, CH2), 
2.50 (brs, 4H, 2CH2), 2.73 (brs, 4H, 2CH2), 3.16 (brs, 6H, 3CH2), 3.32 
(brs, 4H, 2CH2), 3.45 (s, 1H, CH), 5.12 (s, 2H, CH2), 6.63 (s, 1H, ArH), 
6.99 (s, 6H, ArH), 7.56 (brs, 1H, ArH), 7.94 (s, 1H, ArH), 8.65 (brs, 1H, 
quinolone CH), 9.09 (brs, 1H, NH), 15.20 (brs, 1H, OH); 13C NMR: δ 
8.0 (2CH2), 31.2 (CH3), 36.2 (CH), 48.4 (CH2), 49.7 (CH2), 49.8 (2CH2), 
50.8 (CH2), 51.1 (CH2), 68.0 (CH2), 79.9 (CH2), 81.7 (CH2), 82.4 (CH2), 82.5 
(CH2), 107.2 (C), Aryl-C: [104.0 and 104.2 (d, CH, J = 20 Hz), 106.2 (CH), 
111.4 (CH), 113.5 (CH), 115.5 and 115.6 (d, 2CH, J = 10 Hz), 117.7 and 117.8 
(d, 2CH, J = 10 Hz), 119.5 and 119.9 (d, CH, J = 40 Hz), 131.7 (C), 132.5 
(C), 133.1 (C), 139.6 (C), 141.3 (2C), 144.7 and 148.3 (d, C, JC−F = 360 Hz), 
154.5 and 156.1 (d, C, JC−F = 160 Hz), 155.4 and 157.4 (d, C, JC−F = 200 Hz)], 
140.6 (CH), 154.7 (triazole C-3), 157.8 (triazole C-5), 166.4 (2C=O); MS: 
m/z 774.17 ([M + 1] +, 17), 398.26 (100%). Anal. Calcd for C39H42F3N9O3S: 
C, 60.53; H, 5.47; N, 16.29. Found: C, 60.60; H, 5.67; N, 16.51.
4-Benzyl-5-[({3-fluoro-4-[4-(4-fluorophenyl)piperazin-1-yl]phe-
nyl}amino)methyl]-2-(thiomorpholin-4-ylmethyl)-2,4-dihydro-
3H-1,2,4-triazole-3-thione (13a) This compound was obtained 
from 7b and thiomorpholine; yield 67%, method 1, 88%, method 2; 
mp 133–135ºC; IR: νmax 3229 (NH), 3061 (aromatic CH), 2912 (aliphatic 
CH), 1503 (C=N), 1223  cm − 1 (C=S); 1H NMR: δ 2.50 (brs, 4H, 2CH2), 
2.73 (brs, 4H, 2CH2), 2.89 (brs, 4H, 2CH2), 3.18 (brs, 4H, 2CH2), 3.33 
(brs, 4H, 2CH2), 4.73 (s, 2H, CH2), 7.10–7.09 (m, 6H, ArH), 7.26–7.41 
(m, 6H, ArH), 9.58 (brs, 1H, NH); 13C NMR: δ 27.6 (CH2), 47.6 (2CH2), 
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49.7 (2CH2), 49.8 (2CH2), 50.7 (CH2), 50.8 (CH2), 52.7 (2CH2), Aryl-C: 
[115.7 and 115.9 (d, 2CH, J = 20 Hz), 117.7 and 117.8 (d, 2CH, J = 10 Hz), 
119.51and 119.6 (d, CH, J = 10 Hz), 120.2 (CH), 127.3 and 127.4 (d, CH, 
J = 10 Hz), 128.7 (2CH), 128.8 (CH), 129.1 (2CH), 134.4 and 134.5 (d, C, 
J= 10 Hz), 135.9 (C), 136.7 and 136.8 (d, C, J= 10 Hz), 148.3 and 148.4 
(d, C, J = 10 Hz), 149.5 and 153.5 (d, C, JC−F = 400 Hz), 155.5 and 157.8 
(d, C, JC−F = 230 Hz)], 155.9 (triazole C-3), 181.2 (triazole C-5); MS: m/z 
607.88 ([M] +, 45), 532.21 (65), 448.90 (31), 321.56 (76), 201.35 (100%). 
Anal. Calcd for C31H35F2N7S2: C, 61.26; H, 5.80; N, 16.13. Found: C, 
61.60; H, 5.77; N, 16.00.
4-Ethyl-5-[({3-fluoro-4-[4-(4-fluorophenyl)piperazin-1-yl]phe-
nyl}amino)methyl]-2-(thiomorpholin-4-ylmethyl)-2,4-dihydro-
3H-1,2,4-triazole-3-thione (13b) This compound was obtained 
from 7c and thiomorpholine; yield 61% (Method 1), 86% (Method 
2); mp. 180–181°C; IR: νmax 3059 (aromatic CH), 2915 (aliphatic CH), 
1507 (C=N), 1225 cm − 1 (C=S); 1H NMR: δ 1.10 (brs, 3H, CH3), 2.57 (brs, 
4H, 2CH2), 3.02 (brs, 6H, 3CH2), 3.19 (brs, 6H, 3CH2), 3.35 (brs, 4H, 
2CH2), 4.80 (s, 2H, CH2), 6.98 (s, 3H, ArH), 7.05 (s, 4H, ArH), 9.42 (s, 
1H, NH); 13C NMR: δ 13.5 (CH3), 27.5 (CH2), 49.7 (2CH2), 50.7 (CH2), 51.1 
(2CH2), 51.6 (CH2), 52.2 (CH2), 53.4 (CH2), 68.0 (2CH2), Aryl-C:[106.2 
and 106.4 (d, CH, J = 20 Hz), 111.4 (CH), 113.5 (CH), 115.6 and 115.8 (d, 
2CH, J= 20 Hz), 117.8 and 117.8 (d, 2CH, J = 10 Hz), 133.0 and 133.1 (d, C, 
J = 10 Hz), 144.7 and 144.8 (d, C, J = 10 Hz), 148.3 (2C), 155.4 and 157.2 
(d, C, JC−F= 180 Hz)], 154.8 (triazole C-3), 157.8 (triazole C-5); MS: m/z 
545.90 ([M] +, 56), 321.09 (100), 225.89 (57), 201.78 (98), 126.55 (45%). 
Anal. Calcd for C26H33F2N7S2: C, 57.22; H, 6.10; N, 17.97. Found: C, 57.60; 
H, 6.23; N, 17.90.
4-Benzyl-5-[({3-fluoro-4-[4-(4-fluorophenyl)piperazin-1-yl]
phenyl}amino)methyl]-2-[(4-phenylpiperazin-1-yl)methyl]-
2,4-dihydro-3H-1,2,4-triazole-3-thione (14) This compound was 
obtained from 7b and 1-phenylpiperazine; yield 60%, method 1, 
83%, method 2; mp 145–147°C; IR: νmax 3262 (NH), 3059 (aromatic 
CH), 2912 (aliphatic CH), 1506 (C=N), 1224 cm − 1 (C=S); 1H NMR: δ 2.50 
(s, 2H, CH2), 2.73 (s, 2H, CH2), 2.88 (s, 2H, CH2), 3.13 (brs, 6H, 3CH2), 
3.22 (brs, 4H, 2CH2), 3.35 (brs, 4H, 2CH2), 4.74 (s, 2H, CH2), 6.92 (d, 
1H, ArH, J = 4.0 Hz), 7.02–7.09 (m, 7H, ArH), 7.20–7.38 (m, 9H, ArH), 
9.87 (brs, 1H, NH); 13C NMR: δ 47.7 (CH2), 48.1 (CH2), 48.2 (CH2), 48.4 
(CH2), 48.7 (CH2), 49.7 (2CH2), 50.3 (CH2), 50.7 (CH2), 50.8 (CH2), 55.0 
(CH2), Aryl-C: [115.7 and 115.8 (d, 2CH, J = 10 Hz), 115.9 and 116.0 (d, 
CH, J = 10 Hz), 116.1 (CH), 117.8 and 117.9 (d, 2CH, J =10 Hz), 119.5 (CH), 
127.3 (2CH), 127.4 (2CH), 127.9 (2CH), 128.7 (2CH), 129.4 (2CH), 134.4 
and 134.5 (d, C, J = 10 Hz), 136.7 and 136.7 (d, C, J = 10 Hz), 139.4 (C), 
148.3 (2C), 151.6 and 155.5 (d, C, JC−F = 390 Hz), 153.5 and 157.8 (d, C, 
JC−F = 430 Hz)], 155.9 (triazole C-3), 181.3 (triazole C-5); MS: m/z 667.89 
([M + 1] +, 67), 600.21 (38), 556.90 (100), 431.21 (31%). Anal. Calcd for 
C37H40F2N8S: C, 66.64; H, 6.05; N, 16.80. Found: C, 66.60; H, 6.33; N, 
16.61.
Antimicrobial activity assessment
The test microorganisms were obtained from the Hifzissihha Insti-
tute of Refik Saydam (Ankara, Turkey) and were as follows:  E. 
coli ATCC35218, Y. pseudotuberculosis ATCC911, P. aeruginosa 
ATCC43288, E. faecalis ATCC29212, S. aureus ATCC25923, B. cereus 
709 Roma, M. smegmatis ATCC607, C. albicans ATCC60193 and S. 
cerevisia RSKK 251. All compounds were weighed and dissolved in 
dimethyl sulfoxide to prepare a stock solution of 20.0 μg/mL. The 
antimicrobial effects of the compounds were tested quantitatively in 
respective broth media by using double microdilution and the MIC 
values (μg/mL) were determined. The antibacterial and antifungal 
assays were performed in Mueller-Hinton broth (MH) (Difco, Detroit, 
MI, USA) at pH 7.3 and buffered Yeast Nitrogen Base (Difco, Detroit, 
MI, USA) at pH 7.0, respectively. The microdilution test plates were 
incubated for 18–24  h at 35°C. Brain Heart Infusion broth (BHI) 
(Difco, Detriot, MI, USA) was used for M. smegmatis and incubated 
for 48–72  h at 35°C [36]. Ampicillin (10 μg) and fluconazole (5 μg) 
were used as the standard antibacterial and antifungal drugs, 
respectively. DMSO with a dilution of 1 : 10  was used as a solvent 
control.
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